GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » Operating Income

Pharmagreen Biotech (Pharmagreen Biotech) Operating Income : $-0.56 Mil (TTM As of Jun. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech Operating Income?

Pharmagreen Biotech's Operating Income for the three months ended in Jun. 2023 was $-0.08 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.56 Mil.

Warning Sign:

Pharmagreen Biotech Inc has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Pharmagreen Biotech's Operating Income for the three months ended in Jun. 2023 was $-0.08 Mil. Pharmagreen Biotech's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Pharmagreen Biotech's Operating Margin % for the quarter that ended in Jun. 2023 was -7,800.00%.

Pharmagreen Biotech's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pharmagreen Biotech's annualized ROC % for the quarter that ended in Jun. 2023 was -49.52%. Pharmagreen Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.


Pharmagreen Biotech Operating Income Historical Data

The historical data trend for Pharmagreen Biotech's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech Operating Income Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
Operating Income
Get a 7-Day Free Trial -0.67 -0.65 -0.49 -0.75 -1.07

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.18 -0.18 -0.12 -0.08

Pharmagreen Biotech Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmagreen Biotech  (OTCPK:PHBI) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pharmagreen Biotech's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-0.312 * ( 1 - 0% )/( (0.619 + 0.641)/ 2 )
=-0.312/0.63
=-49.52 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Pharmagreen Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.572/( ( (0 + max(-1.69, 0)) + (0 + max(-1.846, 0)) )/ 2 )
=-0.572/( ( 0 + 0 )/ 2 )
=-0.572/0
= %

where Working Capital is:

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0.01 + 0.056) - (1.53 + 0.055 + 0.172)
=-1.69

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0.009 + 0.036) - (1.62 + 0.057 + 0.215)
=-1.846

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Pharmagreen Biotech's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-0.078/0.001
=-7,800.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Pharmagreen Biotech Operating Income Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.